The Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved five anti-TNFα biologics (infliximab, adalimumab, golimumab, etanercept, nd certolizumab), which inhibit or modulate the effects of TNFα, in the treatment of rheumatic (rheumatoid arthritis, anckylosing spondylitis, and psoriasic arthritis) and inflammatory bowel diseases. This evidence concerns the gene TNF and rheumatoid arthritis.